Modeling precision genomic-based radiation dose response in rectal cancer

Modeling precision genomic-based radiation dose response in rectal cancer

Genomic-based risk stratification to personalize radiation dose in rectal cancer. We modeled genomic-based radiation dose response using the previously validated radiosensitivity index (RSI) and the clinically actionable genomic-adjusted radiation dose. RSI of rectal cancer ranged from 0.19 to 0.81...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Future oncology (London, England) England), 2020-10, Vol.16 (30), p.2411-2420
Hauptverfasser: Yuan, Zhigang, Frazer, Marissa, Ahmed, Kamran A, Naqvi, Syeda Mahrukh Hussnain, Schell, Michael J, Felder, Seth, Sanchez, Julian, Dessureault, Sophie, Imanirad, Iman, Kim, Richard D, Torres-Roca, Javier F, Hoffe, Sarah E, Frakes, Jessica M
Format: Artikel
Sprache:eng
Schlagworte:
Cancer therapies
chemoradiation therapy
Chemotherapy
Clinical outcomes
Colorectal cancer
Disease
Gene expression
genomic-adjusted radiation dose
pathologic response
Patients
radiosensitivity
rectal cancer
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Genomic-based risk stratification to personalize radiation dose in rectal cancer. We modeled genomic-based radiation dose response using the previously validated radiosensitivity index (RSI) and the clinically actionable genomic-adjusted radiation dose. RSI of rectal cancer ranged from 0.19 to 0.81 in a bimodal distribution. A pathologic complete response rate of 21% was achieved in tumors with an RSI
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2020-0060